sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
|
eszopiclone
|
ethanol
|
EFFECT
|
Eszopiclone_ddi.xml
|
DDI-DrugBank.d216.s0
|
DDI-DrugBank.d216.s0.p3
|
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.
|
Levetiracetam
|
topiramate
|
NONE
|
Levetiracetam_ddi.xml
|
DDI-DrugBank.d212.s14
|
DDI-DrugBank.d212.s14.p2
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
|
anesthetic solutions
|
tricyclic antidepressants
|
EFFECT
|
Chloroprocaine_ddi.xml
|
DDI-DrugBank.d110.s0
|
DDI-DrugBank.d110.s0.p3
|
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.
|
FORADIL
|
monoamine oxidase inhibitors
|
ADVISE
|
Formoterol_ddi.xml
|
DDI-DrugBank.d103.s3
|
DDI-DrugBank.d103.s3.p9
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
diazoxide
|
naproxen
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p760
|
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
|
dezocine
|
Levo-Dromoran
|
ADVISE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s6
|
DDI-DrugBank.d257.s6.p32
|
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.
|
ketoconazole
|
corticosteroids
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s19
|
DDI-DrugBank.d314.s19.p2
|
Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;
|
Sensipar
|
itraconazole
|
ADVISE
|
Cinacalcet_ddi.xml
|
DDI-DrugBank.d512.s7
|
DDI-DrugBank.d512.s7.p2
|
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
|
picrotoxin
|
phenazepam
|
EFFECT
|
2857099.xml
|
DDI-MedLine.d27.s0
|
DDI-MedLine.d27.s0.p1
|
In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
|
phenobarbital
|
Mefloquine
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s11
|
DDI-DrugBank.d220.s11.p16
|
Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
|
disopyramide
|
TAMBOCOR
|
ADVISE
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s19
|
DDI-DrugBank.d87.s19.p4
|
Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
|
ibuprofen
|
heparin sodium
|
EFFECT
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s2
|
DDI-DrugBank.d488.s2.p29
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
fenoprofen
|
mefenamic acid
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p895
|
Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
|
Itraconazole
|
cyclosporine
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s15
|
DDI-DrugBank.d165.s15.p0
|
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
|
Antizol
|
phenytoin
|
MECHANISM
|
Fomepizole_ddi.xml
|
DDI-DrugBank.d228.s2
|
DDI-DrugBank.d228.s2.p0
|
Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
|
Phenothiazines
|
epinephrine
|
EFFECT
|
Bupivacaine_ddi.xml
|
DDI-DrugBank.d153.s4
|
DDI-DrugBank.d153.s4.p1
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
monoamine oxidase inhibitors
|
fluvoxamine
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p4
|
However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
|
NSAIDs
|
ACE inhibitors
|
EFFECT
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s8
|
DDI-DrugBank.d107.s8.p0
|
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
|
phenytoin
|
CMI
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s6
|
DDI-DrugBank.d238.s6.p20
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
sulfonamides
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p46
|
In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.
|
disulfiram
|
nitrites
|
EFFECT
|
Disulfiram_ddi.xml
|
DDI-DrugBank.d19.s9
|
DDI-DrugBank.d19.s9.p5
|
Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution.
|
ganglionic blocking agents
|
adrenergic neuron blocking agents
|
NONE
|
Captopril_ddi.xml
|
DDI-DrugBank.d175.s11
|
DDI-DrugBank.d175.s11.p0
|
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
|
picrotoxin
|
amizyl
|
EFFECT
|
2857099.xml
|
DDI-MedLine.d27.s0
|
DDI-MedLine.d27.s0.p3
|
These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.
|
warfarin
|
angiotensin converting enzyme inhibitors
|
NONE
|
Abciximab_ddi.xml
|
DDI-DrugBank.d532.s2
|
DDI-DrugBank.d532.s2.p9
|
- Lithium: Generally should not be given with diuretics.
|
Lithium
|
diuretics
|
ADVISE
|
Chlorothiazide_ddi.xml
|
DDI-DrugBank.d46.s15
|
DDI-DrugBank.d46.s15.p0
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
Acetazolamide
|
fluvoxamine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p35
|
Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
|
Codeine
|
sedative-hypnotics
|
EFFECT
|
Codeine_ddi.xml
|
DDI-DrugBank.d464.s0
|
DDI-DrugBank.d464.s0.p4
|
Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
|
alosetron
|
cimetidine
|
ADVISE
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s5
|
DDI-DrugBank.d364.s5.p1
|
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
SSRIs
|
5-HT1 agonists
|
NONE
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s6
|
DDI-DrugBank.d299.s6.p12
|
HMG-CoA Reductase Inhibitors: Simvastatin (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.
|
Simvastatin
|
CYP3A4
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s21
|
DDI-DrugBank.d143.s21.p3
|
In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
|
valproic acid
|
Mefloquine
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s11
|
DDI-DrugBank.d220.s11.p9
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
Chloromycetin
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p3
|
Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
|
digitalis preparations
|
colestipol hydrochloride
|
EFFECT
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s14
|
DDI-DrugBank.d345.s14.p0
|
Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.
|
Ketoconazole
|
corticosteroids
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s22
|
DDI-DrugBank.d314.s22.p3
|
Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
|
caffeine
|
ketoconazole
|
ADVISE
|
Caffeine_ddi.xml
|
DDI-DrugBank.d89.s3
|
DDI-DrugBank.d89.s3.p2
|
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
|
VISTIDE
|
amikacin
|
ADVISE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s3
|
DDI-DrugBank.d260.s3.p3
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
Duloxetine
|
tricyclic antidepressants
|
ADVISE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p1
|
Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.
|
S(-)warfarin
|
Aprepitant
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s16
|
DDI-DrugBank.d382.s16.p9
|
The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
|
adenosine
|
methylxanthines
|
EFFECT
|
Adenosine_ddi.xml
|
DDI-DrugBank.d226.s4
|
DDI-DrugBank.d226.s4.p0
|
therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
|
lansoprazole
|
ampicillin
|
MECHANISM
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s12
|
DDI-DrugBank.d431.s12.p1
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
Butalbital
|
CNS depressants
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p8
|
However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.
|
magnesium
|
antacids
|
NONE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s21
|
DDI-DrugBank.d548.s21.p11
|
Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.
|
quinolones
|
antidiabetic agent
|
EFFECT
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s20
|
DDI-DrugBank.d78.s20.p2
|
BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
|
beta2-agonists
|
tricyclic antidepressants
|
ADVISE
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s6
|
DDI-DrugBank.d284.s6.p5
|
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
|
IOPIDINE
|
anesthetics
|
ADVISE
|
Apraclonidine_ddi.xml
|
DDI-DrugBank.d224.s1
|
DDI-DrugBank.d224.s1.p5
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
lithium
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p25
|
Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
|
amikacin
|
netilmicin
|
NONE
|
Azlocillin_ddi.xml
|
DDI-DrugBank.d9.s0
|
DDI-DrugBank.d9.s0.p7
|
therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
|
carbamazepine
|
phenytoin
|
NONE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s34
|
DDI-DrugBank.d382.s34.p9
|
Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.
|
lithium
|
lithium
|
NONE
|
Candesartan_ddi.xml
|
DDI-DrugBank.d547.s2
|
DDI-DrugBank.d547.s2.p4
|
Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.
|
thyroid preparation
|
anesthetic
|
EFFECT
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s19
|
DDI-DrugBank.d54.s19.p2
|
Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
|
heroin
|
alcohol
|
EFFECT
|
Heroin_ddi.xml
|
DDI-DrugBank.d514.s2
|
DDI-DrugBank.d514.s2.p1
|
The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.
|
enoxacin
|
ranitidine
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s18
|
DDI-DrugBank.d395.s18.p0
|
Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.
|
Aprepitant
|
rifampin
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s38
|
DDI-DrugBank.d382.s38.p3
|
In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.
|
INDOCIN
|
diflunisal
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s1
|
DDI-DrugBank.d82.s1.p0
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
desipramine
|
metoprolol
|
NONE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p66
|
Sumatriptan and D.H.E. 45 (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..
|
Sumatriptan
|
dihydroergotamine mesylate
|
ADVISE
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s2
|
DDI-DrugBank.d410.s2.p1
|
Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.
|
anticoagulants
|
anticonvulsant
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s89
|
DDI-DrugBank.d64.s89.p1
|
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
|
clofibrate
|
anticoagulants
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s90
|
DDI-DrugBank.d64.s90.p26
|
Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.
|
Maalox
|
Maalox
|
NONE
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s37
|
DDI-DrugBank.d438.s37.p3
|
Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
|
Codeine
|
tranquilizers
|
EFFECT
|
Codeine_ddi.xml
|
DDI-DrugBank.d464.s0
|
DDI-DrugBank.d464.s0.p3
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Dilantin
|
Invirase
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p307
|
If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
|
ranitidine
|
magnesium hydroxide
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s5
|
DDI-DrugBank.d558.s5.p23
|
When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
|
atropine
|
pralidoxime
|
EFFECT
|
Atropine_ddi.xml
|
DDI-DrugBank.d222.s0
|
DDI-DrugBank.d222.s0.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
bacitracin
|
anesthetics
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p72
|
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice.
|
theophylline
|
DPCPX
|
NONE
|
7746025.xml
|
DDI-MedLine.d51.s1
|
DDI-MedLine.d51.s1.p6
|
Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
|
penicillin V
|
methotrexate
|
NONE
|
Neomycin_ddi.xml
|
DDI-DrugBank.d330.s2
|
DDI-DrugBank.d330.s2.p5
|
Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.
|
benzodiazepine
|
flumazenil
|
NONE
|
Flumazenil_ddi.xml
|
DDI-DrugBank.d234.s2
|
DDI-DrugBank.d234.s2.p5
|
Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
|
antihistamines
|
tricyclic antidepressants
|
EFFECT
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s1
|
DDI-DrugBank.d448.s1.p1
|
FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.
|
FLUOTHANE
|
non-depolarising muscle relaxant
|
EFFECT
|
Halothane_ddi.xml
|
DDI-DrugBank.d74.s0
|
DDI-DrugBank.d74.s0.p0
|
Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
|
EPA
|
non-steroidal anti-inflammatory drugs
|
INT
|
Icosapent_ddi.xml
|
DDI-DrugBank.d35.s0
|
DDI-DrugBank.d35.s0.p1
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
DURAGESIC
|
phenothiazines
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p20
|
Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
|
nondepolarizing neuromuscular blocking agents
|
carbamazepine
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s13
|
DDI-DrugBank.d60.s13.p1
|
Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
|
Magnesium
|
vitamin D
|
ADVISE
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s15
|
DDI-DrugBank.d98.s15.p4
|
In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.
|
ciclesonide
|
ketoconazole
|
MECHANISM
|
Ciclesonide_ddi.xml
|
DDI-DrugBank.d362.s4
|
DDI-DrugBank.d362.s4.p0
|
Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
|
caffeine
|
phenobarbital
|
ADVISE
|
Caffeine_ddi.xml
|
DDI-DrugBank.d89.s3
|
DDI-DrugBank.d89.s3.p23
|
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
|
topiramate
|
ethinyl estradiol
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s12
|
DDI-DrugBank.d485.s12.p25
|
Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.
|
fluvoxamine
|
diazepam
|
ADVISE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s21
|
DDI-DrugBank.d76.s21.p0
|
Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
|
Epinephrine
|
digitalis
|
ADVISE
|
Epinephrine_ddi.xml
|
DDI-DrugBank.d247.s7
|
DDI-DrugBank.d247.s7.p0
|
As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
|
NUROMAX
|
carbamazepine
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s6
|
DDI-DrugBank.d267.s6.p4
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
carbamazepine
|
sulfonylureas
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p283
|
Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
|
TORADOL
|
TORADOL
|
NONE
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s7
|
DDI-DrugBank.d3.s7.p2
|
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
|
butyrophenones
|
levodopa
|
EFFECT
|
Carbidopa_ddi.xml
|
DDI-DrugBank.d47.s2
|
DDI-DrugBank.d47.s2.p11
|
Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner.
|
estradiol
|
endotoxin
|
EFFECT
|
7600639.xml
|
DDI-MedLine.d39.s6
|
DDI-MedLine.d39.s6.p0
|
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
|
antimuscarinics
|
amantadine
|
NONE
|
Hyoscyamine_ddi.xml
|
DDI-DrugBank.d142.s0
|
DDI-DrugBank.d142.s0.p7
|
Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.
|
sympathomimetics
|
beta adrenergic blockers
|
EFFECT
|
Carbinoxamine_ddi.xml
|
DDI-DrugBank.d389.s3
|
DDI-DrugBank.d389.s3.p1
|
Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
|
selective serotonin reuptake inhibitors
|
doxepin
|
MECHANISM
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s16
|
DDI-DrugBank.d223.s16.p4
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
MAOIs
|
paroxetine
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p12
|
Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.
|
lithium
|
ACE inhibitor
|
EFFECT
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s19
|
DDI-DrugBank.d334.s19.p2
|
Antiepileptic drugs: Potential interactions between Trileptal and other AEDs were assessed in clinical studies.
|
Antiepileptic drugs
|
AEDs
|
NONE
|
Oxcarbazepine_ddi.xml
|
DDI-DrugBank.d307.s11
|
DDI-DrugBank.d307.s11.p1
|
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
|
BREVIBLOC
|
warfarin
|
ADVISE
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s10
|
DDI-DrugBank.d422.s10.p3
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
Levo-Dromoran
|
skeletal muscle relaxants
|
EFFECT
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p10
|
Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.
|
grepafloxacin
|
theophylline
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s7
|
DDI-DrugBank.d78.s7.p2
|
Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.
|
mineral oil
|
vitamin K
|
MECHANISM
|
Menadione_ddi.xml
|
DDI-DrugBank.d139.s5
|
DDI-DrugBank.d139.s5.p3
|
Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC 1 x 109/L).
|
Kineret
|
etanercept
|
EFFECT
|
Anakinra_ddi.xml
|
DDI-DrugBank.d275.s3
|
DDI-DrugBank.d275.s3.p0
|
Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
|
Phospholine Iodide
|
carbamate insecticide
|
EFFECT
|
Echothiophate Iodide_ddi.xml
|
DDI-DrugBank.d377.s0
|
DDI-DrugBank.d377.s0.p3
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
Acetazolamide
|
protease inhibitors
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p43
|
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
|
iodoquinol
|
metronidazole
|
NONE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s13
|
DDI-DrugBank.d263.s13.p100
|
Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
|
Sulindac
|
diflunisal
|
NONE
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s26
|
DDI-DrugBank.d132.s26.p0
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
Phenothiazines
|
Vesprin
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p21
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Trileptal
|
rifampin
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p424
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.